Document is current
Any future updates will be listed below
-
Authors
Vaiana, Alexandra
Behr, Jonathan
Birol, Ryan
Blauwendraat, Cornelis
Casey, Bradford
Chowdhury, Kushan
Citron, Martin
Crapser, Joshua
Dardov, Victoria
Ducotterd, Fiona
Dumanis, Sonya
Dunlop, John
Durborow, Michelle
Fiske, Brian
Golden, Jessica
Hannestad, Jonas
Hung, Wendy
Kemp, Jennifer
Kleiman, Robin
Knight, Adam
Koemeter-Cox, Andrew
Leuchter, Bruce
Logsdon, Bejamin A.
Marreiros, Rita
Miller, Julie E.
Mitchell, Amanda
Mukherjee, Pooja
Navarro, Grace
Nelson, Matthew R.
Nikolich, Karoly
Otis, Tom
Polinski, Nicole
Rastegar-Pouyani, Shima
Reith, Alastair D.
Riley, Ekemini
Rubin, Lee
Ryten, Mina
Sadick, Jessica
Schwabe, Tina
Sherer, Todd
Silvergleid, Sarah
Singleton, Andrew
St. Clair, Lara
Stoehr, Jan
Stone, David J.
Sullivan, Julianna
Tanenbaum, Nicole
Tinelli, Elisa
Trimble, Kate
Wang, Yifei
Weninger, Stacie
Wiggenhauser, Nicolás
Wood, Stephen
Schoepp, Darryle
Buggia-Prevot, Virginie
Padmanabhan, Shalini
Skibinski, Gaia
- License Information
-
More Information
Article History
Received: 3 April 2025
Accepted: 4 June 2025
First Online: 20 June 2025
Competing interests
: The authors entered into an agreement to represent themselves, and not their affiliated institutes throughout the Prioritization and Selection process. However, the authors declare the following potential or perceived conflicts of interest which could bias their thoughts on the targets, either consciously or subconsciously: J.B. is an employee of SV Health Investors, M.C. is an employee of UCB Pharma and has access to stock options of UCB, V.D. is an employee of Technome, J.D. is an employee of Alaida Therapeutics, J.H. is an employee of Gain Therapeutics, R.K. is an employee of Myrobalan Therapeutics, A.K. is the Founder and a shareholder of Neuron23, he is affiliated with Neuro.VC, which is an investor in Vanqua Bio, Neuron23, and Capsida Biotherapeutics, B.L. is the CEO of Neurvati Neurosciences, a company focused on in-licensing clinical-stage molecules across the neuroscience landscape, not currently active in PD/neurodegenerative disease but could engage around opportunities in this space in the future, B.A.L. is an employee of Cajal Neuroscience, M.R.N. is an employee of Deerfield Management and Genscience LLC., T.O. is an employee of Lario Therapeutics, which works on CACNA1E and CACNA1D targets, J. Sadick and V.B.P. are employed by and have equity in Valo Health, a company engaged in various drug discovery and development projects, including certain neuroimmunology targets, T. Schwabe is an employee of Nine Square Therapeutics and currently works on the Trpml1 target, which was selected on the shortlist of targets for further evaluation, S.S. is an employee of Schrodinger, Inc., J. Stoehr and D.J.S. are employees of AbbVie Inc., E.T. is an employee of Golgi Neurosciences, working on TREM2, MCOLN1 and CACNA1D, S. Weninger is an employee of F-Prime and sits on the boards of Tenvie and Atalanta, S. Wood is an employee and stockholder of Neuron23, Inc. A.D.R., D.S., and A.M. are active consultants in the biopharmaceutical space. The remaining authors declare no financial competing interests: A.V., R.B., C.B., B.C., K.C., J.C., F.D., S.D., M.D., B.F., J.G.,W.H., J.K., A.K.C., R.M., J.E.M., P.M., G.N., K.N., N.P., S.R.P., E.R., L.R., M.R., T. Sherer, A.S., L.S., J. Sullivan, N.T., K.T., Y.W., N.W., S.P., G.S.
